EA200100652A1 - Соединение (варианты) и способ его образования, способ усиления клеточной абсорбции соединения с аминогруппой, способ пролонгирования удерживания в крови и ткани млекопитающего биологически активного соединения с аминогруппой и способ его доставки во внутреннюю часть клетки, фармацевтическая композиция, фармацевтический препарат - Google Patents
Соединение (варианты) и способ его образования, способ усиления клеточной абсорбции соединения с аминогруппой, способ пролонгирования удерживания в крови и ткани млекопитающего биологически активного соединения с аминогруппой и способ его доставки во внутреннюю часть клетки, фармацевтическая композиция, фармацевтический препаратInfo
- Publication number
- EA200100652A1 EA200100652A1 EA200100652A EA200100652A EA200100652A1 EA 200100652 A1 EA200100652 A1 EA 200100652A1 EA 200100652 A EA200100652 A EA 200100652A EA 200100652 A EA200100652 A EA 200100652A EA 200100652 A1 EA200100652 A1 EA 200100652A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino group
- biologically active
- delivery
- cell
- mammals
- Prior art date
Links
- 125000003277 amino group Chemical group 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000014759 maintenance of location Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11178498P | 1998-12-10 | 1998-12-10 | |
| PCT/US1999/029119 WO2000034236A1 (en) | 1998-12-10 | 1999-12-09 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200100652A1 true EA200100652A1 (ru) | 2001-12-24 |
Family
ID=22340445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100652A EA200100652A1 (ru) | 1998-12-10 | 1999-12-09 | Соединение (варианты) и способ его образования, способ усиления клеточной абсорбции соединения с аминогруппой, способ пролонгирования удерживания в крови и ткани млекопитающего биологически активного соединения с аминогруппой и способ его доставки во внутреннюю часть клетки, фармацевтическая композиция, фармацевтический препарат |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6590071B1 (https=) |
| EP (1) | EP1137631B1 (https=) |
| JP (1) | JP4637362B2 (https=) |
| KR (1) | KR100676419B1 (https=) |
| CN (1) | CN1168711C (https=) |
| AR (1) | AR021604A1 (https=) |
| AT (1) | ATE265429T1 (https=) |
| AU (1) | AU764035B2 (https=) |
| CA (1) | CA2354142A1 (https=) |
| DE (1) | DE69916885T2 (https=) |
| EA (1) | EA200100652A1 (https=) |
| ES (1) | ES2220141T3 (https=) |
| HK (1) | HK1045681B (https=) |
| IL (2) | IL143578A0 (https=) |
| TW (1) | TWI242000B (https=) |
| WO (1) | WO2000034236A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US8541548B2 (en) * | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
| US7442764B2 (en) * | 1999-06-07 | 2008-10-28 | Mirns Bio Corporation | Reversible modification of amine-containing compounds |
| US7019113B2 (en) * | 1999-06-07 | 2006-03-28 | Mirus Bio Corporation | Reversible modification of membrane interaction |
| US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| KR100989647B1 (ko) | 2001-09-24 | 2010-10-26 | 오레곤 헬스 앤드 사이언스 유니버시티 | 식습관의 변화 |
| EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
| US8008355B2 (en) * | 2002-03-11 | 2011-08-30 | Roche Madison Inc. | Endosomolytic poly(vinyl ether) polymers |
| US8138383B2 (en) * | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
| WO2004048530A2 (en) * | 2002-11-22 | 2004-06-10 | Carnegie Mellon University | Compositions and methods for the reversible capture of biomolecules |
| US20040151766A1 (en) * | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| US20050054612A1 (en) * | 2003-09-08 | 2005-03-10 | Monahan Sean D. | Delivery by labile hydrophobic modification of drugs |
| US20090074885A1 (en) * | 2003-09-08 | 2009-03-19 | Roche Madison Inc. | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells |
| FR2880627B1 (fr) * | 2005-01-07 | 2007-05-18 | Silab Sa | Procede d'obtention d'un principe actif pour l'eclat du teint, principe actif obtenu et compositions associees |
| KR100726281B1 (ko) * | 2006-07-31 | 2007-06-11 | (주)아모레퍼시픽 | 신규 지방산 에스테르 화합물 및 이를 유효성분으로함유하는 당뇨 및 비만치료용 조성물 |
| KR20090091145A (ko) * | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | 지질화된 인터페론 및 이의 용도 |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| WO2009059984A2 (en) * | 2007-11-06 | 2009-05-14 | F. Hoffmann-La Roche Ag | Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2962504A (en) * | 1960-11-29 | Production of maleic anhydride | ||
| US5144011A (en) * | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4480106A (en) * | 1981-10-28 | 1984-10-30 | Ciba-Geigy Corporation | Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4764368A (en) | 1984-08-29 | 1988-08-16 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4889916A (en) | 1985-11-19 | 1989-12-26 | The Johns Hopkins University | Protein label and drug delivery system |
| US4751286A (en) | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5017693A (en) | 1987-12-02 | 1991-05-21 | Neorx Corporation | Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5066490A (en) | 1988-06-01 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Protein crosslinking reagents cleavable within acidified intracellular vesicles |
| US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
| FI101678B1 (fi) * | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| US5907030A (en) * | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| PL183698B1 (pl) * | 1995-03-17 | 2002-06-28 | Novo Nordisk As | Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny |
| US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5907530A (en) | 1995-08-30 | 1999-05-25 | Samsung Electronics Co., Ltd. | Optical pickup device |
| IL129177A0 (en) * | 1996-09-26 | 2000-02-17 | Univ Southern California | Methods and compositions for lipidization of hydrophilic molecules |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
-
1999
- 1999-12-06 TW TW088121325A patent/TWI242000B/zh active
- 1999-12-09 CA CA002354142A patent/CA2354142A1/en not_active Abandoned
- 1999-12-09 EA EA200100652A patent/EA200100652A1/ru unknown
- 1999-12-09 JP JP2000586684A patent/JP4637362B2/ja not_active Expired - Fee Related
- 1999-12-09 EP EP99967238A patent/EP1137631B1/en not_active Expired - Lifetime
- 1999-12-09 WO PCT/US1999/029119 patent/WO2000034236A1/en not_active Ceased
- 1999-12-09 IL IL14357899A patent/IL143578A0/xx active IP Right Grant
- 1999-12-09 DE DE69916885T patent/DE69916885T2/de not_active Expired - Lifetime
- 1999-12-09 AT AT99967238T patent/ATE265429T1/de not_active IP Right Cessation
- 1999-12-09 US US09/457,587 patent/US6590071B1/en not_active Expired - Fee Related
- 1999-12-09 AR ARP990106275A patent/AR021604A1/es unknown
- 1999-12-09 KR KR1020017007259A patent/KR100676419B1/ko not_active Expired - Fee Related
- 1999-12-09 HK HK02107065.3A patent/HK1045681B/zh not_active IP Right Cessation
- 1999-12-09 CN CNB998142441A patent/CN1168711C/zh not_active Expired - Fee Related
- 1999-12-09 ES ES99967238T patent/ES2220141T3/es not_active Expired - Lifetime
- 1999-12-09 AU AU23556/00A patent/AU764035B2/en not_active Ceased
-
2001
- 2001-06-05 IL IL143578A patent/IL143578A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1350519A (zh) | 2002-05-22 |
| CN1168711C (zh) | 2004-09-29 |
| DE69916885D1 (de) | 2004-06-03 |
| WO2000034236A1 (en) | 2000-06-15 |
| CA2354142A1 (en) | 2000-06-15 |
| JP2002531543A (ja) | 2002-09-24 |
| AR021604A1 (es) | 2002-07-31 |
| HK1045681A1 (en) | 2002-12-06 |
| HK1045681B (zh) | 2005-05-20 |
| EP1137631A1 (en) | 2001-10-04 |
| ES2220141T3 (es) | 2004-12-01 |
| DE69916885T2 (de) | 2005-04-07 |
| JP4637362B2 (ja) | 2011-02-23 |
| AU764035B2 (en) | 2003-08-07 |
| TWI242000B (en) | 2005-10-21 |
| US6590071B1 (en) | 2003-07-08 |
| KR20010080749A (ko) | 2001-08-22 |
| AU2355600A (en) | 2000-06-26 |
| KR100676419B1 (ko) | 2007-02-05 |
| ATE265429T1 (de) | 2004-05-15 |
| EP1137631B1 (en) | 2004-04-28 |
| IL143578A0 (en) | 2002-04-21 |
| IL143578A (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200100652A1 (ru) | Соединение (варианты) и способ его образования, способ усиления клеточной абсорбции соединения с аминогруппой, способ пролонгирования удерживания в крови и ткани млекопитающего биологически активного соединения с аминогруппой и способ его доставки во внутреннюю часть клетки, фармацевтическая композиция, фармацевтический препарат | |
| ES2545219T3 (es) | Fragmentos de péptido para inducir la síntesis de las proteínas de la matriz extracelular | |
| EP1198254B1 (de) | Träger-pharmaka-konjugate | |
| CN102827284B (zh) | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 | |
| BE1004357A4 (fr) | Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments. | |
| EA200100464A1 (ru) | Модифицированные пептиды как терапевтические агенты | |
| EA200200220A1 (ru) | Нацеливающие мультимерные визуализирующие агенты с механизмом мультилокусного связывания | |
| JP2018058851A (ja) | 薬物コンジュゲート、コンジュゲーション方法およびその使用 | |
| EA200000601A1 (ru) | Сайт - специфичное получение конъюгатов grf с полиэтиленгликолем | |
| EA200400067A1 (ru) | Конъюгаты гксф | |
| DE3587579D1 (de) | Pharmazeutische Zubereitung enthaltend eine Tetrahydropyrrolverbindung als aktiven Bestandteil und Verfahren zur Herstellung dieser Tetrapyrrolverbindung. | |
| DK1105409T3 (da) | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter | |
| JP2005097320A (ja) | 増強循環エフェクター組成物および方法 | |
| EP0966303A2 (en) | Polypeptide conjugates for transporting substances across cell membranes | |
| EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
| IT1164225B (it) | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione | |
| PL356391A1 (pl) | Estry chlorofilu i bakteriochlorofilu, sposób ichwytwarzania oraz zawierające je kompozycje farmaceutyczne | |
| EA199700143A1 (ru) | Способ и композиция ждя липидизации гидрофильных молекул | |
| EA200001111A1 (ru) | КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН | |
| AU1385699A (en) | Novel conjugates of rgd-containing peptides and endogenous carriers | |
| WO2013180537A2 (ko) | 피부 투과성 펩타이드 | |
| BR0109266A (pt) | Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto | |
| CA2123576A1 (en) | Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock | |
| EP0358234A2 (en) | Intranasal calcitonin formulations | |
| CA2069943A1 (en) | Synthetic calcitonin peptides |